Incidence of SARS-CoV-2 infection and associated risk factors among staff and residents at homeless shelters in King County, Washington: an active surveillance study.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
10 07 2023
Historique:
medline: 8 8 2023
pubmed: 10 7 2023
entrez: 10 7 2023
Statut: epublish

Résumé

Homeless shelter residents and staff may be at higher risk of SARS-CoV-2 infection. However, SARS-CoV-2 infection estimates in this population have been reliant on cross-sectional or outbreak investigation data. We conducted routine surveillance and outbreak testing in 23 homeless shelters in King County, Washington, to estimate the occurrence of laboratory-confirmed SARS-CoV-2 infection and risk factors during 1 January 2020-31 May 2021. Symptom surveys and nasal swabs were collected for SARS-CoV-2 testing by RT-PCR for residents aged ≥3 months and staff. We collected 12,915 specimens from 2,930 unique participants. We identified 4.74 (95% CI 4.00-5.58) SARS-CoV-2 infections per 100 individuals (residents: 4.96, 95% CI 4.12-5.91; staff: 3.86, 95% CI 2.43-5.79). Most infections were asymptomatic at the time of detection (74%) and detected during routine surveillance (73%). Outbreak testing yielded higher test positivity than routine surveillance (2.7% versus 0.9%). Among those infected, residents were less likely to report symptoms than staff. Participants who were vaccinated against seasonal influenza and were current smokers had lower odds of having an infection detected. Active surveillance that includes SARS-CoV-2 testing of all persons is essential in ascertaining the true burden of SARS-CoV-2 infections among residents and staff of congregate settings.

Identifiants

pubmed: 37424310
doi: 10.1017/S0950268823001036
pii: S0950268823001036
pmc: PMC10540173
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e129

Subventions

Organisme : CDC HHS
ID : 75D30120C09322
Pays : United States

Références

Am J Infect Control. 2021 Jun;49(6):694-700
pubmed: 33631305
N Engl J Med. 2020 Jul 9;383(2):185-187
pubmed: 32356944
Influenza Other Respir Viruses. 2023 Jan;17(1):e13092
pubmed: 36610058
Lancet Public Health. 2020 Apr;5(4):e186-e187
pubmed: 32171054
Workplace Health Saf. 2022 May;70(5):235-241
pubmed: 35112601
BMC Public Health. 2022 Jul 12;22(1):1327
pubmed: 35820879
Sci Rep. 2021 May 26;11(1):11025
pubmed: 34040014
Emerg Infect Dis. 2022 Jan;28(1):76-84
pubmed: 34856112
J Infect Dis. 2022 Aug 24;226(2):217-224
pubmed: 35091746
Vaccines (Basel). 2020 Oct 15;8(4):
pubmed: 33076405
Lancet. 2023 Mar 11;401(10379):833-842
pubmed: 36930674
CMAJ. 2020 Jun 29;192(26):E716-E719
pubmed: 32601252
Clin Infect Dis. 2021 Jul 15;73(2):324-327
pubmed: 32744615
JAMA. 2020 Jun 2;323(21):2191-2192
pubmed: 32338732
NPJ Prim Care Respir Med. 2021 Feb 26;31(1):10
pubmed: 33637750
Asian J Psychiatr. 2022 Mar;69:102987
pubmed: 34979474
J Public Health Manag Pract. 2021 May-Jun 01;27(3):285-294
pubmed: 33762544
BMC Med. 2021 May 7;19(1):116
pubmed: 33962621
Immunity. 2021 Oct 12;54(10):2172-2176
pubmed: 34626549
JAMA Netw Open. 2021 Dec 1;4(12):e2138464
pubmed: 34902035
MMWR Morb Mortal Wkly Rep. 2020 Jul 10;69(27):864-869
pubmed: 32644981
Lancet Public Health. 2021 Apr;6(4):e202-e209
pubmed: 33556328
Expert Rev Vaccines. 2020 Oct;19(10):919-936
pubmed: 32940090
Int J Infect Dis. 2021 Feb;103:243-245
pubmed: 33321208
Int J Popul Data Sci. 2021 Dec 02;5(4):1695
pubmed: 35097224
J Clin Med Res. 2021 Dec;13(12):549-555
pubmed: 35059073
Ann Intern Med. 2021 Jan;174(1):42-49
pubmed: 32931328
West J Emerg Med. 2020 Aug 17;21(5):1048-1053
pubmed: 32970553
Trials. 2020 Nov 23;21(1):956
pubmed: 33228787
Sci Total Environ. 2023 Sep 15;891:164402
pubmed: 37244609
EClinicalMedicine. 2021 Aug;38:101032
pubmed: 34316550
Lancet. 2014 Oct 25;384(9953):1529-40
pubmed: 25390578
Vaccines (Basel). 2020 Sep 16;8(3):
pubmed: 32947988

Auteurs

Julia H Rogers (JH)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Department of Epidemiology, University of Washington, Seattle, WA, USA.

Sarah N Cox (SN)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Department of Epidemiology, University of Washington, Seattle, WA, USA.

Amy C Link (AC)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.

Gift Nwanne (G)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.

Peter D Han (PD)

Brotman Baty Institute for Precision Medicine, Seattle, WA, USA.

Brian Pfau (B)

Brotman Baty Institute for Precision Medicine, Seattle, WA, USA.

Eric J Chow (EJ)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.

Caitlin R Wolf (CR)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.

Michael Boeckh (M)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

James P Hughes (JP)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Department of Biostatistics, University of Washington, Seattle, WA, USA.

M Elizabeth Halloran (ME)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Department of Biostatistics, University of Washington, Seattle, WA, USA.

Timothy M Uyeki (TM)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

M Mia Shim (MM)

Public Health - Seattle & King County, Seattle, WA, USA.
Department of Medicine, University of Washington, Seattle, WA, USA.

Jeffrey Duchin (J)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Public Health - Seattle & King County, Seattle, WA, USA.

Janet A Englund (JA)

Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Washington, Seattle Children's Research Institute, Seattle, WA, USA.

Emily Mosites (E)

Office of the Deputy Director for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Melissa A Rolfes (MA)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lea A Starita (LA)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.

Helen Y Chu (HY)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH